疏水性 CPP/HDO 共轭物:寡核苷酸主导的 PROTAC 输送新领域。

IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY RSC medicinal chemistry Pub Date : 2024-09-26 DOI:10.1039/D4MD00546E
Miyako Naganuma, Nobumichi Ohoka, Motoharu Hirano, Daishi Watanabe, Genichiro Tsuji, Takao Inoue and Yosuke Demizu
{"title":"疏水性 CPP/HDO 共轭物:寡核苷酸主导的 PROTAC 输送新领域。","authors":"Miyako Naganuma, Nobumichi Ohoka, Motoharu Hirano, Daishi Watanabe, Genichiro Tsuji, Takao Inoue and Yosuke Demizu","doi":"10.1039/D4MD00546E","DOIUrl":null,"url":null,"abstract":"<p >Proteolysis-targeting chimeras (PROTACs) have emerged as a potent strategy for inducing targeted degradation of proteins, offering promising therapeutic potential to treat diseases such as cancer. However, oligonucleotide-based PROTACs face significant delivery challenges because of their anionic nature and chemical instability. To address these issues, we developed a novel hydrophobic cell-penetrating peptide (CPP) and heteroduplex oligonucleotide (HDO)-conjugated PROTAC, <strong>CPP/HDO-PROTAC</strong>, to enhance intracellular delivery and degradation efficiency. <strong>CPP/HDO-PROTAC</strong> was designed to enter the cell through the activity of the conjugated hydrophobic CPP and release decoy oligonucleotide-based PROTACs by RNase H-mediated RNA strand breaks. Our findings demonstrated that <strong>CPP/HDO-PROTAC</strong> binds to the estrogen receptor α (ERα) with higher affinity than previous constructs, significantly degrades ERα in MCF-7 human breast cancer cells and inhibits cell proliferation at 10 μM. This research highlights the potential of <strong>CPP/HDO-PROTAC</strong> as a viable method for delivering and activating decoy oligonucleotide-based PROTACs within cells, overcoming the limitations of traditional transfection methods and paving the way for their clinical application.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" 11","pages":" 3695-3703"},"PeriodicalIF":4.1000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hydrophobic CPP/HDO conjugates: a new frontier in oligonucleotide-warheaded PROTAC delivery†\",\"authors\":\"Miyako Naganuma, Nobumichi Ohoka, Motoharu Hirano, Daishi Watanabe, Genichiro Tsuji, Takao Inoue and Yosuke Demizu\",\"doi\":\"10.1039/D4MD00546E\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Proteolysis-targeting chimeras (PROTACs) have emerged as a potent strategy for inducing targeted degradation of proteins, offering promising therapeutic potential to treat diseases such as cancer. However, oligonucleotide-based PROTACs face significant delivery challenges because of their anionic nature and chemical instability. To address these issues, we developed a novel hydrophobic cell-penetrating peptide (CPP) and heteroduplex oligonucleotide (HDO)-conjugated PROTAC, <strong>CPP/HDO-PROTAC</strong>, to enhance intracellular delivery and degradation efficiency. <strong>CPP/HDO-PROTAC</strong> was designed to enter the cell through the activity of the conjugated hydrophobic CPP and release decoy oligonucleotide-based PROTACs by RNase H-mediated RNA strand breaks. Our findings demonstrated that <strong>CPP/HDO-PROTAC</strong> binds to the estrogen receptor α (ERα) with higher affinity than previous constructs, significantly degrades ERα in MCF-7 human breast cancer cells and inhibits cell proliferation at 10 μM. This research highlights the potential of <strong>CPP/HDO-PROTAC</strong> as a viable method for delivering and activating decoy oligonucleotide-based PROTACs within cells, overcoming the limitations of traditional transfection methods and paving the way for their clinical application.</p>\",\"PeriodicalId\":21462,\"journal\":{\"name\":\"RSC medicinal chemistry\",\"volume\":\" 11\",\"pages\":\" 3695-3703\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RSC medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00546e\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00546e","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

蛋白质分解靶向嵌合体(PROTACs)已成为一种诱导蛋白质靶向降解的有效策略,为治疗癌症等疾病提供了巨大的治疗潜力。然而,基于寡核苷酸的 PROTAC 因其阴离子性质和化学不稳定性而面临着巨大的递送挑战。为了解决这些问题,我们开发了一种新型疏水性细胞穿透肽(CPP)和杂双寡核苷酸(HDO)共轭的 PROTAC(CPP/HDO-PROTAC),以提高细胞内递送和降解效率。CPP/HDO-PROTAC 的设计目的是通过共轭疏水性 CPP 的活性进入细胞,并通过 RNase H 介导的 RNA 链断裂释放基于诱饵寡核苷酸的 PROTAC。我们的研究结果表明,CPP/HDO-PROTAC 与雌激素受体 α(ERα)的结合亲和力高于以往的构建物,能显著降解 MCF-7 人类乳腺癌细胞中的ERα,并在 10 μM 的浓度下抑制细胞增殖。这项研究强调了 CPP/HDO-PROTAC 作为一种可行的方法在细胞内递送和激活基于诱饵寡核苷酸的 PROTAC 的潜力,克服了传统转染方法的局限性,为其临床应用铺平了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hydrophobic CPP/HDO conjugates: a new frontier in oligonucleotide-warheaded PROTAC delivery†

Proteolysis-targeting chimeras (PROTACs) have emerged as a potent strategy for inducing targeted degradation of proteins, offering promising therapeutic potential to treat diseases such as cancer. However, oligonucleotide-based PROTACs face significant delivery challenges because of their anionic nature and chemical instability. To address these issues, we developed a novel hydrophobic cell-penetrating peptide (CPP) and heteroduplex oligonucleotide (HDO)-conjugated PROTAC, CPP/HDO-PROTAC, to enhance intracellular delivery and degradation efficiency. CPP/HDO-PROTAC was designed to enter the cell through the activity of the conjugated hydrophobic CPP and release decoy oligonucleotide-based PROTACs by RNase H-mediated RNA strand breaks. Our findings demonstrated that CPP/HDO-PROTAC binds to the estrogen receptor α (ERα) with higher affinity than previous constructs, significantly degrades ERα in MCF-7 human breast cancer cells and inhibits cell proliferation at 10 μM. This research highlights the potential of CPP/HDO-PROTAC as a viable method for delivering and activating decoy oligonucleotide-based PROTACs within cells, overcoming the limitations of traditional transfection methods and paving the way for their clinical application.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.80
自引率
2.40%
发文量
129
期刊最新文献
Back cover Property-based optimisation of PROTACs. A practical guide for the assay-dependent characterisation of irreversible inhibitors. Adjuvant strategies to tackle mcr-mediated polymyxin resistance. Antibacterial activity of the structurally novel C-2 amine-substituted analogues based on quinoxaline.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1